Report Code: CMI45011

Published Date: April 2024

Pages: 320+

Category: Healthcare

Report Snapshot

CAGR: 5.8%
8.2B
2023
8.6B
2024
14.4B
2033

Source: CMI

Study Period: 2024-2033
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Purdue Pharma L.P.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the global Cancer Pain Market is expected to record a CAGR of 5.8% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 8.6 Billion. By 2033, the valuation is anticipated to reach USD 14.4 Billion.

The cancer pain market refers to the sector of the healthcare industry dedicated to addressing the pain experienced by individuals afflicted with cancer. It encompasses a wide range of pharmaceutical and non-pharmaceutical interventions aimed at managing and alleviating pain symptoms associated with various forms and stages of cancer.

This market includes the development, manufacturing, and distribution of analgesic medications, palliative care services, medical devices, and supportive therapies tailored specifically for cancer patients. As cancer incidence rates continue to rise globally, the demand for effective pain management solutions within this market segment remains high, driving ongoing innovation and investment in research and development efforts.

Cancer Pain Market – Significant Growth Factors

The Cancer Pain Market presents significant growth opportunities due to several factors:

  • Increasing Cancer Prevalence: As cancer incidence rates continue to rise worldwide, particularly in aging populations, the demand for effective pain management solutions escalates, driving growth in the cancer pain market.
  • Advancements in Pain Management Therapies: Ongoing research and development efforts lead to the introduction of innovative pharmacological and non-pharmacological pain management therapies tailored specifically for cancer patients, enhancing treatment options and improving patient outcomes.
  • Growing Focus on Palliative Care: There is a heightened emphasis on providing comprehensive palliative care, including pain management, to improve the quality of life for cancer patients, driving the demand for specialized pain relief interventions and supportive services.
  • Technological Innovations in Drug Delivery: Advancements in drug delivery technologies, such as implantable devices and targeted drug delivery systems, offer new opportunities to optimize pain management in cancer patients, facilitating more precise dosing and improved efficacy.
  • Expansion of Telemedicine and Remote Monitoring: The increasing adoption of telemedicine and remote monitoring solutions presents an opportunity to enhance accessibility to pain management services for cancer patients, particularly in underserved or remote areas, by facilitating virtual consultations and remote symptom monitoring.
  • Personalized Medicine and Precision Oncology: The growing focus on personalized medicine and precision oncology opens doors for the development of tailored pain management strategies based on individual patient characteristics, tumor biology, and treatment responses, offering the potential for more effective and personalized pain relief interventions.

Cancer Pain Market – Mergers and Acquisitions

The Cancer Pain Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Cancer Pain Market include:

  • In 2022, Parker Laboratories Inc. will expand its analgesics line, introducing Helix CBD Therapy Cream, CBD Clinical Cream, and Tri-Active Therapy Cream to its HelixTM brand, complementing its existing range of pain relief creams and medical contact media.
  • In 2022, Venus Remedies Limited unveils the launch of its consumer healthcare division, offering a range of products dedicated to pain management, further diversifying its portfolio and expanding its presence in the consumer health market segment.
  • In 2022, Gamida Cell’s allogeneic cell therapy Omisirge received FDA approval, promising to enhance access to stem cell transplants and improve patient outcomes. This milestone marks a significant advancement in the field of cell therapy and offers hope for patients in need of transplantation.
  • In 2022, Guardant Health introduced the Shield test, a non-invasive blood-based screening method for detecting colorectal cancer. This test eliminates the need for sedation and dietary changes, offering a less painful and more convenient option. It detects early colorectal cancer signals in the bloodstream, enhancing early detection efforts.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Cancer Pain Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Cancer Pain Market Bispecific Antibodies Market Liver Cancer Market
CAGR 5.8% (Approx) CAGR 24.1% (Approx) CAGR 14.5% (Approx)
USD 14.4 Billion by 2033 USD 53.8 Billion by 2033 USD 16.3 Billion by 2033

Cancer Pain Market – Significant Threats

The Cancer Pain Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • Regulatory Challenges: Stringent regulations and compliance requirements imposed by regulatory agencies can pose challenges for companies developing and commercializing pain management therapies. Delays in approvals or stringent safety and efficacy standards may hinder market entry and limit product availability.
  • Patent Expirations: The expiration of patents for existing pain medications can lead to increased competition from generic alternatives, resulting in pricing pressures and erosion of market share for branded drugs. This can impact revenues and profitability for pharmaceutical companies operating in the cancer pain market.
  • Opioid Epidemic Concerns: Heightened scrutiny and regulatory restrictions surrounding opioid medications due to concerns over addiction, misuse, and overdose pose a significant threat to the cancer pain market. Increased regulations and prescribing limitations may restrict access to opioid-based pain relief therapies for cancer patients who require them.
  • Healthcare Cost Containment Measures: Cost-containment efforts by healthcare payers and institutions may lead to reimbursement challenges and pricing pressures for pain management therapies. Reduced reimbursement rates or formulary restrictions can impact market access and uptake of novel pain relief treatments.
  • Competitive Landscape: Intense competition within the cancer pain market from established pharmaceutical companies and emerging biotech firms can pose challenges to market penetration and differentiation of products. Companies must invest in research and development to innovate new therapies and differentiate themselves from competitors to maintain market share and profitability.

Global Cancer Pain Market 2024–2033 (By Drug Class)

www.custommarketinsight.com

Category-Wise Insights

By Drug Class:

  • Opioids: Opioids are potent analgesic drugs commonly used for severe cancer pain. Trends include increasing concerns over opioid misuse and addiction, leading to stricter regulations and the development of abuse-deterrent formulations. Despite challenges, opioids remain a cornerstone in cancer pain management due to their efficacy.
  • NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): NSAIDs are commonly used for mild to moderate cancer pain and inflammation. Trends include a shift towards safer and more selective NSAIDs to minimize gastrointestinal and cardiovascular risks. NSAIDs offer an alternative or adjunct to opioids in cancer pain management strategies.
  • Others: Other drug classes in cancer pain management include adjuvant medications such as antidepressants, anticonvulsants, and corticosteroids. Trends include the exploration of novel adjuvant therapies targeting neuropathic pain pathways and inflammatory mechanisms to complement traditional analgesics and improve pain control in cancer patients.

By Indication

  • Lung Cancer: Lung cancer refers to malignancies originating in the lungs. In the cancer pain market, trends include a focus on targeted therapies and immunotherapies to manage pain, alongside advancements in palliative care approaches tailored to address respiratory symptoms and improve the quality of life for patients.
  • Colorectal Cancer: Colorectal cancer affects the colon or rectum. In the cancer pain market, trends involve the development of personalized pain management strategies, such as enhanced analgesic regimens and minimally invasive interventions, to alleviate symptoms and optimize patient comfort during treatment and recovery.
  • Breast Cancer: Breast cancer originates in breast tissue. Trends in the cancer pain market include the integration of multidisciplinary approaches, incorporating surgical, pharmacological, and complementary therapies to address pain associated with breast cancer treatments, with a growing emphasis on individualized pain management plans to meet patient needs.
  • Prostate Cancer: Prostate cancer affects the prostate gland. In the cancer pain market, trends encompass the utilization of hormone therapy and radiation techniques to manage pain stemming from prostate cancer progression or treatment-related side effects. Additionally, emerging targeted therapies aim to address specific molecular pathways implicated in prostate cancer pain.
  • Blood Cancer: Blood cancers, such as leukemia, lymphoma, and myeloma, originate in the blood or bone marrow. In the cancer pain market, trends involve the implementation of tailored pain management strategies, including chemotherapy, immunotherapy, and supportive care measures, to address pain associated with disease progression, treatment-induced neuropathy, and bone marrow involvement.
  • Others: Trends in the cancer pain market for other cancers include the exploration of novel pain relief modalities, such as gene therapy and neurostimulation, tailored to specific tumor types and patient populations, to enhance pain control and improve quality of life.

Global Cancer Pain Market 2024–2033 (By End-Users)

www.custommarketinsight.com

Route of Administration

  • Oral: Oral administration involves medication taken through the mouth. In the cancer pain market, oral medications offer convenience and ease of administration for patients. Trends include the development of long-acting formulations and combination therapies to improve efficacy and patient adherence.
  • Parenteral: Parenteral administration involves delivery via injection or infusion. In the cancer pain market, parenteral routes offer rapid onset of action and precise dosing. Trends include the development of novel delivery systems such as implantable pumps and targeted injections for localized pain relief.
  • Others: Other routes of administration in the cancer pain market include transdermal patches, rectal suppositories, and intranasal sprays. These alternatives offer non-invasive options for patients with difficulty swallowing or tolerating oral medications. Trends include the adoption of innovative drug delivery technologies to enhance efficacy and patient comfort.

By End User

  • Hospitals: Hospitals serve as primary centers for cancer treatment, offering comprehensive pain management services. Trends include the integration of multidisciplinary pain management teams and the adoption of advanced pain relief modalities such as nerve blocks and patient-controlled analgesia systems.
  • Homecare: Homecare services provide cancer patients with pain management support in the comfort of their homes. Trends include the expansion of telehealth solutions for remote monitoring and virtual consultations, empowering patients to manage pain effectively outside clinical settings while enhancing accessibility to supportive care.
  • Specialty Clinics: Specialty clinics specialize in cancer care and pain management, offering targeted interventions tailored to individual patient needs. Trends include the incorporation of complementary therapies such as acupuncture and massage into pain management protocols, providing holistic approaches to alleviate cancer-related pain.
  • Others: This category encompasses various end users such as palliative care centers, rehabilitation facilities, and outpatient clinics. Trends may include the development of innovative pain management programs, collaborations with community organizations, and the implementation of patient-centric approaches to enhance pain relief and supportive care for cancer patients.

By Distribution Channel

  • Hospital Pharmacy: Hospital pharmacies within the cancer pain market serve as critical distribution channels for pain management medications and supportive care therapies, providing access to specialized treatments tailored to cancer patients. Trends include increased adoption of multidisciplinary pain management teams and integration of palliative care services within hospital settings.
  • Online Pharmacy: Online pharmacies offer convenience and accessibility for cancer patients seeking pain relief medications and supportive care products. Trends include the rise of telemedicine and virtual consultations, facilitating remote access to pain management services, and the expansion of e-commerce platforms catering to the oncology market.
  • Retail Pharmacy: Retail pharmacies play a vital role in providing over-the-counter and prescription pain relief medications to cancer patients, complementing hospital and specialty pharmacy services. Trends include the integration of oncology-focused services and educational programs within retail pharmacy settings to support cancer patients’ comprehensive care needs.

Report Scope

Feature of the Report Details
Market Size in 2024 USD 8.6 Billion
Projected Market Size in 2033 USD 14.4 Billion
Market Size in 2023 USD 8.2 Billion
CAGR Growth Rate 5.8% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Drug Class, Indication, Route of Administration, End-Users, Distribution Channel and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Cancer Pain Market – Regional Analysis

The Cancer Pain Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America: In North America, the cancer pain market is characterized by a growing emphasis on personalized medicine and precision oncology, with increasing investments in genomic research and targeted therapy development. Additionally, there’s a trend towards the integration of comprehensive palliative care services within oncology centers to address the holistic needs of cancer patients.
  • Europe: In Europe, there’s a notable trend towards the adoption of value-based healthcare models, driving efforts to optimize cost-effectiveness and improve patient outcomes in cancer pain management. Moreover, there’s a growing focus on collaborative research initiatives and cross-border partnerships to accelerate innovation and enhance access to advanced pain relief therapies.
  • Asia-Pacific: The Asia-Pacific region is witnessing a surge in demand for cancer pain management solutions due to the rising prevalence of cancer and expanding access to healthcare services. Key trends include the increasing adoption of telemedicine and digital health technologies to overcome geographic barriers and enhance patient access to pain relief interventions.
  • LAMEA (Latin America, Middle East, and Africa): In the LAMEA region, the cancer pain market is characterized by disparities in access to healthcare services and limited resources, posing challenges to effective pain management. However, there’s a trend towards the development of innovative low-cost pain relief solutions and collaborative initiatives aimed at improving cancer care infrastructure and access to essential medications.

Global Cancer Pain Market 2024–2033 (By Billion)

www.custommarketinsight.com

Competitive Landscape – Cancer Pain Market

The Cancer Pain Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

  • Purdue Pharma L.P.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Merck & Co. Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Abbott Laboratories
  • Bristol Myers Squibb Company
  • Mallinckrodt Pharmaceuticals
  • Endo International plc
  • Mylan N.V.
  • Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

New players entering the cancer pain market are adopting innovation and development strategies to carve their niche. Startups and emerging biotech firms are leveraging advancements in drug delivery systems, personalized medicine, and digital health technologies to introduce novel pain management therapies tailored to specific cancer types and patient profiles.

Meanwhile, key players dominating the market, such as Pfizer, Johnson & Johnson, and Novartis, maintain their stronghold through extensive research capabilities, robust product portfolios, global market presence, strategic collaborations, and strong brand recognition, ensuring their leadership position in providing effective pain relief solutions for cancer patients.

The Cancer Pain Market is segmented as follows:

By Drug Class

  • Opioids
  • NSAIDs
  • Others

By Indication

  • Lung cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood Cancer
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Cancer Pain Market, (2024 – 2033) (USD Billion)
    • 2.2 Global Cancer Pain Market: snapshot
  • Chapter 3. Global Cancer Pain Market – Industry Analysis
    • 3.1 Cancer Pain Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Increasing Cancer Prevalence
      • 3.2.2 Advancements in Pain Management Therapies
      • 3.2.3 Growing Focus on Palliative Care
      • 3.2.4 Technological Innovations in Drug Delivery
      • 3.2.5 Expansion of Telemedicine and Remote Monitoring
      • 3.2.6 Personalized Medicine and Precision Oncology.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Drug Class
      • 3.7.2 Market Attractiveness Analysis By Indication
      • 3.7.3 Market Attractiveness Analysis By Route of Administration
      • 3.7.4 Market Attractiveness Analysis By End-Users
      • 3.7.5 Market Attractiveness Analysis By Distribution Channel
  • Chapter 4. Global Cancer Pain Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Cancer Pain Market: Company Market Share, 2023
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Cancer Pain Market – Drug Class Analysis
    • 5.1 Global Cancer Pain Market Overview: By Drug Class
      • 5.1.1 Global Cancer Pain Market Share, By Drug Class, 2023 and 2033
    • 5.2 Opioids
      • 5.2.1 Global Cancer Pain Market by Opioids, 2024 – 2033 (USD Billion)
    • 5.3 NSAIDs
      • 5.3.1 Global Cancer Pain Market by NSAIDs, 2024 – 2033 (USD Billion)
    • 5.4 Others
      • 5.4.1 Global Cancer Pain Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 6. Global Cancer Pain Market – Indication Analysis
    • 6.1 Global Cancer Pain Market Overview: By Indication
      • 6.1.1 Global Cancer Pain Market Share, By Indication, 2023 and 2033
    • 6.2 Lung cancer
      • 6.2.1 Global Cancer Pain Market by Lung Cancer, 2024 – 2033 (USD Billion)
    • 6.3 Colorectal Cancer
      • 6.3.1 Global Cancer Pain Market by Colorectal Cancer, 2024 – 2033 (USD Billion)
    • 6.4 Breast Cancer
      • 6.4.1 Global Cancer Pain Market by Breast Cancer, 2024 – 2033 (USD Billion)
    • 6.5 Prostate Cancer
      • 6.5.1 Global Cancer Pain Market by Prostate Cancer, 2024 – 2033 (USD Billion)
    • 6.6 Blood Cancer
      • 6.6.1 Global Cancer Pain Market by Blood Cancer, 2024 – 2033 (USD Billion)
    • 6.7 Others
      • 6.7.1 Global Cancer Pain Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 7. Global Cancer Pain Market – Route of Administration Analysis
    • 7.1 Global Cancer Pain Market Overview: By Route of Administration
      • 7.1.1 Global Cancer Pain Market Share, By Route of Administration, 2023 and 2033
    • 7.2 Oral
      • 7.2.1 Global Cancer Pain Market by Oral, 2024 – 2033 (USD Billion)
    • 7.3 Parenteral
      • 7.3.1 Global Cancer Pain Market by Parenteral, 2024 – 2033 (USD Billion)
    • 7.4 Others
      • 7.4.1 Global Cancer Pain Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 8. Global Cancer Pain Market – End-Users Analysis
    • 8.1 Global Cancer Pain Market Overview: By End-Users
      • 8.1.1 Global Cancer Pain Market Share, By End-Users, 2023 and 2033
    • 8.2 Hospitals
      • 8.2.1 Global Cancer Pain Market by Hospitals, 2024 – 2033 (USD Billion)
    • 8.3 Homecare
      • 8.3.1 Global Cancer Pain Market by Homecare, 2024 – 2033 (USD Billion)
    • 8.4 Specialty Clinics
      • 8.4.1 Global Cancer Pain Market by Specialty Clinics, 2024 – 2033 (USD Billion)
    • 8.5 Others
      • 8.5.1 Global Cancer Pain Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 9. Global Cancer Pain Market – Distribution Channel Analysis
    • 9.1 Global Cancer Pain Market Overview: By Distribution Channel
      • 9.1.1 Global Cancer Pain Market Share, By Distribution Channel, 2023 and 2033
    • 9.2 Hospital Pharmacy
      • 9.2.1 Global Cancer Pain Market by Hospital Pharmacy, 2024 – 2033 (USD Billion)
    • 9.3 Online Pharmacy
      • 9.3.1 Global Cancer Pain Market by Online Pharmacy, 2024 – 2033 (USD Billion)
    • 9.4 Retail Pharmacy
      • 9.4.1 Global Cancer Pain Market by Retail Pharmacy, 2024 – 2033 (USD Billion)
  • Chapter 10. Cancer Pain’s Market – Regional Analysis
    • 10.1 Global Cancer Pain’s Market Regional Overview
    • 10.2 Global Cancer Pain’s Market Share, by Region, 2023 & 2033 (USD Billion)
    • 10.3. North America
      • 10.3.1 North America Cancer Pain’s Market, 2024 – 2033 (USD Billion)
        • 10.3.1.1 North America Cancer Pain’s Market, by Country, 2024 – 2033 (USD Billion)
    • 10.4 North America Cancer Pain’s Market, by Drug Class, 2024 – 2033
      • 10.4.1 North America Cancer Pain’s Market, by Drug Class, 2024 – 2033 (USD Billion)
    • 10.5 North America Cancer Pain’s Market, by Indication, 2024 – 2033
      • 10.5.1 North America Cancer Pain’s Market, by Indication, 2024 – 2033 (USD Billion)
    • 10.6 North America Cancer Pain’s Market, by Route of Administration, 2024 – 2033
      • 10.6.1 North America Cancer Pain’s Market, by Route of Administration, 2024 – 2033 (USD Billion)
    • 10.7 North America Cancer Pain’s Market, by End-Users, 2024 – 2033
      • 10.7.1 North America Cancer Pain’s Market, by End-Users, 2024 – 2033 (USD Billion)
    • 10.8 North America Cancer Pain’s Market, by Distribution Channel, 2024 – 2033
      • 10.8.1 North America Cancer Pain’s Market, by Distribution Channel, 2024 – 2033 (USD Billion)
    • 10.9. Europe
      • 10.9.1 Europe Cancer Pain’s Market, 2024 – 2033 (USD Billion)
        • 10.9.1.1 Europe Cancer Pain’s Market, by Country, 2024 – 2033 (USD Billion)
    • 10.10 Europe Cancer Pain’s Market, by Drug Class, 2024 – 2033
      • 10.10.1 Europe Cancer Pain’s Market, by Drug Class, 2024 – 2033 (USD Billion)
    • 10.11 Europe Cancer Pain’s Market, by Indication, 2024 – 2033
      • 10.11.1 Europe Cancer Pain’s Market, by Indication, 2024 – 2033 (USD Billion)
    • 10.12 Europe Cancer Pain’s Market, by Route of Administration, 2024 – 2033
      • 10.12.1 Europe Cancer Pain’s Market, by Route of Administration, 2024 – 2033 (USD Billion)
    • 10.13 Europe Cancer Pain’s Market, by End-Users, 2024 – 2033
      • 10.13.1 Europe Cancer Pain’s Market, by End-Users, 2024 – 2033 (USD Billion)
    • 10.14 Europe Cancer Pain’s Market, by Distribution Channel, 2024 – 2033
      • 10.14.1 Europe Cancer Pain’s Market, by Distribution Channel, 2024 – 2033 (USD Billion)
    • 10.15. Asia Pacific
      • 10.15.1 Asia Pacific Cancer Pain’s Market, 2024 – 2033 (USD Billion)
        • 10.15.1.1 Asia Pacific Cancer Pain’s Market, by Country, 2024 – 2033 (USD Billion)
    • 10.16 Asia Pacific Cancer Pain’s Market, by Drug Class, 2024 – 2033
      • 10.16.1 Asia Pacific Cancer Pain’s Market, by Drug Class, 2024 – 2033 (USD Billion)
    • 10.17 Asia Pacific Cancer Pain’s Market, by Indication, 2024 – 2033
      • 10.17.1 Asia Pacific Cancer Pain’s Market, by Indication, 2024 – 2033 (USD Billion)
    • 10.18 Asia Pacific Cancer Pain’s Market, by Route of Administration, 2024 – 2033
      • 10.18.1 Asia Pacific Cancer Pain’s Market, by Route of Administration, 2024 – 2033 (USD Billion)
    • 10.19 Asia Pacific Cancer Pain’s Market, by End-Users, 2024 – 2033
      • 10.19.1 Asia Pacific Cancer Pain’s Market, by End-Users, 2024 – 2033 (USD Billion)
    • 10.20 Asia Pacific Cancer Pain’s Market, by Distribution Channel, 2024 – 2033
      • 10.20.1 Asia Pacific Cancer Pain’s Market, by Distribution Channel, 2024 – 2033 (USD Billion)
    • 10.21. Latin America
      • 10.21.1 Latin America Cancer Pain’s Market, 2024 – 2033 (USD Billion)
        • 10.21.1.1 Latin America Cancer Pain’s Market, by Country, 2024 – 2033 (USD Billion)
    • 10.22 Latin America Cancer Pain’s Market, by Drug Class, 2024 – 2033
      • 10.22.1 Latin America Cancer Pain’s Market, by Drug Class, 2024 – 2033 (USD Billion)
    • 10.23 Latin America Cancer Pain’s Market, by Indication, 2024 – 2033
      • 10.23.1 Latin America Cancer Pain’s Market, by Indication, 2024 – 2033 (USD Billion)
    • 10.24 Latin America Cancer Pain’s Market, by Route of Administration, 2024 – 2033
      • 10.24.1 Latin America Cancer Pain’s Market, by Route of Administration, 2024 – 2033 (USD Billion)
    • 10.25 Latin America Cancer Pain’s Market, by End-Users, 2024 – 2033
      • 10.25.1 Latin America Cancer Pain’s Market, by End-Users, 2024 – 2033 (USD Billion)
    • 10.26 Latin America Cancer Pain’s Market, by Distribution Channel, 2024 – 2033
      • 10.26.1 Latin America Cancer Pain’s Market, by Distribution Channel, 2024 – 2033 (USD Billion)
    • 10.27. The Middle-East and Africa
      • 10.27.1 The Middle-East and Africa Cancer Pain’s Market, 2024 – 2033 (USD Billion)
        • 10.27.1.1 The Middle-East and Africa Cancer Pain’s Market, by Country, 2024 – 2033 (USD Billion)
    • 10.28 The Middle-East and Africa Cancer Pain’s Market, by Drug Class, 2024 – 2033
      • 10.28.1 The Middle-East and Africa Cancer Pain’s Market, by Drug Class, 2024 – 2033 (USD Billion)
    • 10.29 The Middle-East and Africa Cancer Pain’s Market, by Indication, 2024 – 2033
      • 10.29.1 The Middle-East and Africa Cancer Pain’s Market, by Indication, 2024 – 2033 (USD Billion)
    • 10.30 The Middle-East and Africa Cancer Pain’s Market, by Route of Administration, 2024 – 2033
      • 10.30.1 The Middle-East and Africa Cancer Pain’s Market, by Route of Administration, 2024 – 2033 (USD Billion)
    • 10.31 The Middle-East and Africa Cancer Pain’s Market, by End-Users, 2024 – 2033
      • 10.31.1 The Middle-East and Africa Cancer Pain’s Market, by End-Users, 2024 – 2033 (USD Billion)
    • 10.32 The Middle-East and Africa Cancer Pain’s Market, by Distribution Channel, 2024 – 2033
      • 10.32.1 The Middle-East and Africa Cancer Pain’s Market, by Distribution Channel, 2024 – 2033 (USD Billion)
  • Chapter 11. Company Profiles
    • 11.1 Purdue Pharma L.P.
      • 11.1.1 Overview
      • 11.1.2 Financials
      • 11.1.3 Product Portfolio
      • 11.1.4 Business Strategy
      • 11.1.5 Recent Developments
    • 11.2 Teva Pharmaceutical Industries Ltd.
      • 11.2.1 Overview
      • 11.2.2 Financials
      • 11.2.3 Product Portfolio
      • 11.2.4 Business Strategy
      • 11.2.5 Recent Developments
    • 11.3 Pfizer Inc.
      • 11.3.1 Overview
      • 11.3.2 Financials
      • 11.3.3 Product Portfolio
      • 11.3.4 Business Strategy
      • 11.3.5 Recent Developments
    • 11.4 Johnson & Johnson
      • 11.4.1 Overview
      • 11.4.2 Financials
      • 11.4.3 Product Portfolio
      • 11.4.4 Business Strategy
      • 11.4.5 Recent Developments
    • 11.5 Novartis AG
      • 11.5.1 Overview
      • 11.5.2 Financials
      • 11.5.3 Product Portfolio
      • 11.5.4 Business Strategy
      • 11.5.5 Recent Developments
    • 11.6 GlaxoSmithKline plc
      • 11.6.1 Overview
      • 11.6.2 Financials
      • 11.6.3 Product Portfolio
      • 11.6.4 Business Strategy
      • 11.6.5 Recent Developments
    • 11.7 AstraZeneca plc
      • 11.7.1 Overview
      • 11.7.2 Financials
      • 11.7.3 Product Portfolio
      • 11.7.4 Business Strategy
      • 11.7.5 Recent Developments
    • 11.8 Merck & Co. Inc.
      • 11.8.1 Overview
      • 11.8.2 Financials
      • 11.8.3 Product Portfolio
      • 11.8.4 Business Strategy
      • 11.8.5 Recent Developments
    • 11.9 Bayer AG
      • 11.9.1 Overview
      • 11.9.2 Financials
      • 11.9.3 Product Portfolio
      • 11.9.4 Business Strategy
      • 11.9.5 Recent Developments
    • 11.10 Eli Lilly and Company
      • 11.10.1 Overview
      • 11.10.2 Financials
      • 11.10.3 Product Portfolio
      • 11.10.4 Business Strategy
      • 11.10.5 Recent Developments
    • 11.11 Abbott Laboratories
      • 11.11.1 Overview
      • 11.11.2 Financials
      • 11.11.3 Product Portfolio
      • 11.11.4 Business Strategy
      • 11.11.5 Recent Developments
    • 11.12 Bristol Myers Squibb Company
      • 11.12.1 Overview
      • 11.12.2 Financials
      • 11.12.3 Product Portfolio
      • 11.12.4 Business Strategy
      • 11.12.5 Recent Developments
    • 11.13 Mallinckrodt Pharmaceuticals
      • 11.13.1 Overview
      • 11.13.2 Financials
      • 11.13.3 Product Portfolio
      • 11.13.4 Business Strategy
      • 11.13.5 Recent Developments
    • 11.14 Endo International plc
      • 11.14.1 Overview
      • 11.14.2 Financials
      • 11.14.3 Product Portfolio
      • 11.14.4 Business Strategy
      • 11.14.5 Recent Developments
    • 11.15 Mylan N.V.
      • 11.15.1 Overview
      • 11.15.2 Financials
      • 11.15.3 Product Portfolio
      • 11.15.4 Business Strategy
      • 11.15.5 Recent Developments
    • 11.16 Others.
      • 11.16.1 Overview
      • 11.16.2 Financials
      • 11.16.3 Product Portfolio
      • 11.16.4 Business Strategy
      • 11.16.5 Recent Developments
List Of Figures

Figures No 1 to 39

List Of Tables

Tables No 1 to 127

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2032

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2032
  • Market revenue estimates and forecasts up to 2032, by technology
  • Market revenue estimates and forecasts up to 2032, by application
  • Market revenue estimates and forecasts up to 2032, by type
  • Market revenue estimates and forecasts up to 2032, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Purdue Pharma L.P.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Merck & Co. Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Abbott Laboratories
  • Bristol Myers Squibb Company
  • Mallinckrodt Pharmaceuticals
  • Endo International plc
  • Mylan N.V.
  • Others

FAQs

The key factors driving the Market are Increasing Cancer Prevalence, Advancements in Pain Management Therapies, Growing Focus on Palliative Care, Technological Innovations in Drug Delivery, Expansion of Telemedicine and Remote Monitoring, Personalized Medicine and Precision Oncology.

The “Opioids” category dominated the market in 2023.

The key players in the market are Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson, Novartis AG, GlaxoSmithKline plc, AstraZeneca plc, Merck & Co. Inc., Bayer AG, Eli Lilly and Company, Abbott Laboratories, Bristol Myers Squibb Company, Mallinckrodt Pharmaceuticals, Endo International plc, Mylan N.V., Others.

“North America” had the largest share in the Cancer Pain Market.

The global market is projected to grow at a CAGR of 5.8% during the forecast period, 2024-2033.

The Cancer Pain Market size was valued at USD 8.6 Billion in 2024.

PURCHASE OPTIONS

$

3490


$

4490


$

5490


$

1950


powerbi pdf
$

6200

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • PDF, Excel, Power Point and Power BI.
  • Every Year Free Update ( Apr – Apr)
  • Personalized market brief by author
  • Can be accessible by unlimited users.
  • Free 50% or 90 hours of customization.
  • Up to 50 Company Profiles
  • Free post-sale service assistance with guarantee
  • 40% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account team.
  • Service guarantee available.

Want to customize this report?
100% FREE CUSTOMIZATION!